Alnylam reported third quarter 2026 total revenues of $1.46 billion, up 17% from a year earlier, led by net product revenues of $1.29 billion, up 52%. GAAP net income reached $2.17 billion, or $15.72 per diluted share, but that figure includes a $1.9 billion income tax benefit, while GAAP income from operations fell 6% to $345.8 million. The company reiterated its full-year 2026 guidance.
Total revenues were $1,458.1 million versus $1,249.0 million in Q3 2025, up 17%.
Total net product revenues were $1,292 million, up 52%, with Total TTR net product revenues at $1,150 million.
GAAP income from operations was $345.8 million, down 6% from $368.0 million, while GAAP diluted EPS was $15.72 versus $2.14, helped by a $1.9 billion tax benefit.
Full-year 2026 total net product revenues guidance of $4,700 million to $5,100 million was reiterated.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Alnylam Pharmaceuticals, Inc.'s 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$3.71B
+65.2%
$2.33
—
8.4%
FY2024
$2.25B
+23.0%
$-2.18
—
-12.4%
FY2023
$1.83B
+76.2%
$-3.52
—
-24.1%
FY2022
$1.04B
+22.9%
$-9.30
—
-109.0%
FY2021
$844.29M
+71.3%
$-7.20
—
-101.0%
Frequently asked questions
When is Alnylam Pharmaceuticals's next earnings date?
Alnylam Pharmaceuticals has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Alnylam Pharmaceuticals earn last quarter?
For the quarter ended Sep 2026, Alnylam Pharmaceuticals reported diluted EPS of $15.72 (+634.6% year over year) on revenue of $1.46B (+16.7%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.